Ethyl 3,4-dihydroxybenzoateCAS# 3943-89-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 3943-89-3 | SDF | Download SDF |
PubChem ID | 77547 | Appearance | White crystalline powder |
Formula | C9H10O4 | M.Wt | 182.17 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | ethyl 3,4-dihydroxybenzoate | ||
SMILES | CCOC(=O)C1=CC(=C(C=C1)O)O | ||
Standard InChIKey | KBPUBCVJHFXPOC-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C9H10O4/c1-2-13-9(12)6-3-4-7(10)8(11)5-6/h3-5,10-11H,2H2,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Ethyl 3,4-dihydroxybenzoate Dilution Calculator
Ethyl 3,4-dihydroxybenzoate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.4894 mL | 27.4469 mL | 54.8938 mL | 109.7876 mL | 137.2345 mL |
5 mM | 1.0979 mL | 5.4894 mL | 10.9788 mL | 21.9575 mL | 27.4469 mL |
10 mM | 0.5489 mL | 2.7447 mL | 5.4894 mL | 10.9788 mL | 13.7234 mL |
50 mM | 0.1098 mL | 0.5489 mL | 1.0979 mL | 2.1958 mL | 2.7447 mL |
100 mM | 0.0549 mL | 0.2745 mL | 0.5489 mL | 1.0979 mL | 1.3723 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Kamebanin
Catalog No.:BCN5449
CAS No.:39388-57-3
- Neurotensin
Catalog No.:BCC5842
CAS No.:39379-15-2
- BCTC
Catalog No.:BCC7797
CAS No.:393514-24-4
- 2,3-Dihydroxy-4-methoxybenzoic acid
Catalog No.:BCN6534
CAS No.:3934-81-4
- Tiplaxtinin(PAI-039)
Catalog No.:BCC6439
CAS No.:393105-53-8
- Sotalol
Catalog No.:BCC4356
CAS No.:3930-20-9
- Ginsenoside Compound K
Catalog No.:BCN1246
CAS No.:39262-14-1
- Oxyresveratrol 2-O-beta-D-glucopyranoside
Catalog No.:BCN1448
CAS No.:392274-22-5
- (E)-Cinnamyl-(Z)-p-coumarate
Catalog No.:BCN7694
CAS No.:391682-51-2
- Ac-His-OH.H2O
Catalog No.:BCC2953
CAS No.:39145-52-3
- Trimebutine
Catalog No.:BCC4615
CAS No.:39133-31-8
- N-Me-Ala-OH.HCl
Catalog No.:BCC2619
CAS No.:3913-67-5
- Eleutheroside E
Catalog No.:BCN1083
CAS No.:39432-56-9
- Boceprevir
Catalog No.:BCC1435
CAS No.:394730-60-0
- 3-Acetylcoumarin
Catalog No.:BCC8603
CAS No.:3949-36-8
- CC-401
Catalog No.:BCC4269
CAS No.:395104-30-0
- Sinigrin
Catalog No.:BCN8484
CAS No.:3952-98-5
- Asperosaponin VI
Catalog No.:BCN1256
CAS No.:39524-08-8
- Nitrendipine
Catalog No.:BCC4381
CAS No.:39562-70-4
- Triamterene
Catalog No.:BCC5074
CAS No.:396-01-0
- Z-Sar-OH
Catalog No.:BCC3339
CAS No.:39608-31-6
- Pasireotide
Catalog No.:BCC5300
CAS No.:396091-73-9
- LY364947
Catalog No.:BCC5085
CAS No.:396129-53-6
- Isoshinanolone
Catalog No.:BCN7986
CAS No.:39626-91-0
[Steroids and aromatic derivatives from Euphorbia micractina].[Pubmed:27141676]
Zhongguo Zhong Yao Za Zhi. 2015 Dec;40(23):4639-44.
From an ethanol extract of Euphorbia micractina roots, seven steroids fifteen aromatic derivatives were isolated by a combination of various chromatographic techniques, including column chromatography over macroporous resin, silica gel, and Sephadex LH-20 and reversed-phase HPLC. Their structures were elucidated by spectroscopic data analysis as stigamast-5-ene-3beta, 7alpha-diol(1), stigamast-5-ene-3beta,7beta-diol(2), stigmast-5-en-3beta-ol-7-one(3), stigmast-4-en-6beta-ol-3-one(4), stigmast-1, 4-dien-3-one(5), stigmast-3,6-dione(6), beta-sitosterol(7), scopoletin(8), aesculetin(9), 6-hydroxy-5,7-dimethoxycoumarin(10), quercetin(11), 3,3', 4'-tri-O-methylellagic acid(12), p-hydroxyphenylethyl anisate(13), m-hydroxyphenylethyl alcohol(14), (E)-cinnamic acid(15), (E)-ferulic acid(16), 3,4-dihydroxybenzoic acid(17), vanillic acid(18), p-hydroxybenzoic acid(19), Ethyl 3,4-dihydroxybenzoate (20), ethyl gallate(21), and methyl gallate(22). These compounds were obtained from this plant for the first time.
Preconditioning with ethyl 3,4-dihydroxybenzoate augments aerobic respiration in rat skeletal muscle.[Pubmed:27800513]
Hypoxia (Auckl). 2016 May 13;4:109-120.
Muscle respiratory capacity decides the amount of exertion one's skeletal muscle can undergo, and endurance exercise is believed to increase it. There are also certain preconditioning methods by which muscle respiratory and exercise performance can be enhanced. In this study, preconditioning with Ethyl 3,4-dihydroxybenzoate (EDHB), a prolyl hydroxylase domain enzyme inhibitor, has been investigated to determine its effect on aerobic metabolism and bioenergetics in skeletal muscle, thus facilitating boost in physical performance in a rat model. We observed that EDHB supplementation increases aerobic metabolism via upregulation of HIF-mediated GLUT1 and GLUT4, thus enhancing glucose uptake in muscles. There was also a twofold rise in the activity of enzymes of tricarboxylic acid (TCA) cycle and glycolysis, ie, hexokinase and phosphofructokinase. There was an increase in citrate synthase and succinate dehydrogenase activity, resulting in the rise in the levels of ATP due to enhanced Krebs cycle activity as substantiated by enhanced acetyl-CoA levels in EDHB-treated rats as compared to control group. Increased lactate dehydrogenase activity, reduced expression of monocarboxylate transporter 1, and increase in monocarboxylate transporter 4 suggest transport of lactate from muscle to blood. There was a concomitant decrease in plasma lactate, which might be due to enhanced transport of lactate from blood to the liver. This was further supported by the rise in liver pyruvate levels and liver glycogen levels in EDHB-supplemented rats as compared to control rats. These results suggest that EDHB supplementation leads to improved physical performance due to the escalation of aerobic respiration quotient, ie, enhanced muscle respiratory capacity.
MicroRNA-17-5p mediates hypoxia-induced autophagy and inhibits apoptosis by targeting signal transducer and activator of transcription 3 in vascular smooth muscle cells.[Pubmed:28450922]
Exp Ther Med. 2017 Mar;13(3):935-941.
The aim of the present study was to investigate hypoxia-induced apoptosis and autophagy in vascular smooth muscle cells (VSMCs) and the underlying molecular mechanisms of microRNA (miR)-17-5p responses in an anaerobic environment. The results revealed that miR-17-5p expression was significantly upregulated in VSMCs subjected to hypoxic conditions (P<0.05) and lower miR-17-5p levels were observed in Ethyl 3,4-dihydroxybenzoate-treated and hypoxia inducible factor-1 loss-of-function cells. Additionally, it was demonstrated that miR-17-5p is associated with hypoxia-induced autophagy, which was confirmed by upregulating the light chain 3-II/LC3-I ratio and downregulating nucleoporin p62. Cell apoptosis was inhibited in response to hypoxia, and levels of pro-apoptotic proteins B-cell lymphoma 2-associated X protein and p-caspase were markedly decreased when VSMCs were subjected to hypoxic conditions. Furthermore, expression of signal transducer and activator of transcription 3 (STAT3) decreased when cells were transfected with overexpressing miR-17-5p and subjected to hypoxic conditions, and the combination of miR-17-5p loss-of-function and hypoxia induced greater upregulation in the protein expression of STAT3 compared with a single treatment for hypoxia in VSMCs. In conclusion, miR-17-5p may be a novel hypoxia-responsive miR and hypoxia may induce protective autophagy and anti-apoptosis in VSMCs by targeting STAT3.